We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Current Opportunities

San Francisco, CA
Closes: 06 Jun 2021 15:55
San Francisco, CA
Closes: 10 May 2021 21:17
San Francisco, CA
Closes: 10 May 2021 21:07
San Francisco, CA
Closes: 23 Apr 2021 07:14
This site is powered by SnapHire (www.snaphire.com)